IMMVIRA
Immvira was founded in Shenzhen China in May of 2015 by Prof. Bernard Roizman of University of Chicago and Prof. Grace Zhou formerly a Research Associate Professor at University of Chicago, Prof. Thomas Shenk of Princeton University, Prof. Richard Whitley of University of Alabama, Prof. Ralph Weichselbaum of University of Chicago.
IMMVIRA
Industry:
Clinical Trials
Founded:
2015-01-01
Address:
Shenzhen, Guangdong, China
Country:
China
Website Url:
http://www.immvira-theravir.com
Total Employee:
1+
Status:
Active
Contact:
(0755)28291816
Total Funding:
90.49 M USD
Technology used in webpage:
SPF Microsoft Azure DNS China Telecom Tencent QQ Mail Xinnet DNS
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Genetron Health
Genetron Health is a world-leading expert in precision medicine.
Current Employees Featured
Founder
Investors List
GL Ventures
GL Ventures investment in Series C - Immvira
WinDigital Capital
WinDigital Capital investment in Series C - Immvira
Lanting Capital
Lanting Capital investment in Series C - Immvira
Octagon Capital Partners
Octagon Capital Partners investment in Series C - Immvira
Hillhouse Capital Group
Hillhouse Capital Group investment in Series C - Immvira
OrbiMed
OrbiMed investment in Series C - Immvira
Greater Bay Area Homeland Development Fund
Greater Bay Area Homeland Development Fund investment in Series C - Immvira
China Merchants Capital
China Merchants Capital investment in Series C - Immvira
Shanghai Healthcare Capital
Shanghai Healthcare Capital investment in Series B - Immvira
Cowin Capital
Cowin Capital investment in Series B - Immvira
Key Employee Changes
| Date | New article |
|---|---|
| 2020-07-01 | Immvira Announces the Appointment of Carl Yeung as Chief Financial Officer |
Official Site Inspections
http://www.immvira-theravir.com Semrush global rank: 4.26 M Semrush visits lastest month: 2.73 K
- Host name: 104.21.2.249
- IP address: 104.21.2.249
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Immvira"
ๅ ณไบๆไปฌ - immviragroup.com
ImmVira is a biotechnology company focused on development of new generation novel anti-cancer drug vectors driven by clinical benefits in oncology and non-oncology fields. Leveraging naturally evolved delivery mechanisms and โฆSee details»
Immvira - Crunchbase Company Profile & Funding
Immvira was founded in Shenzhen China in May of 2015 by Prof. Bernard Roizman of University of Chicago and Prof. Grace Zhou formerly a Research Associate Professor at University of Chicago, Prof. Thomas Shenk of โฆSee details»
Immvira Company Profile | Management and Employees List
Immvira Profile and History ImmVira is a biotechnology company focused on genetically modified oncolytic viruses as potential cancer therapeutics. The company has developed science, โฆSee details»
ImmVira - LinkedIn
ImmVira | 212 followers on LinkedIn. A company focusing on developing aboard range of anti-cancer therapies | VISION ABOVE AND BEYOND Immvira was founded in May of 2015 by โฆSee details»
ImmVira Company Profile 2024: Valuation, Funding
ImmVira has raised $91M. Who are ImmViraโs investors? China Merchants Capital , Jiangsu Wuzhong Industrial Company , Unifortune Investment, China Merchants Venture Capital , and Greater Bay Area Homeland are 5 of 21 โฆSee details»
Immvira Pharma Co., Limited - Drug pipelines, Patents ... - Patsnap
Explore Immvira Pharma Co., Limited with its drug pipeline, therapeutic area, technology platform, 11 clinical trials, 19 news, and 3 literature, Disease Domain:Neoplasms, Hemic and Lymphatic โฆSee details»
Immvira - Funding, Financials, Valuation & Investors - Crunchbase
Immviraโs scientific objectives are based on numerous experimental designs of oHSV and outcomes of clinical trials. Search Crunchbase. Start Free Trial . ... How much funding has this โฆSee details»
Immvira - Overview, News & Similar companies | ZoomInfo.com
Nov 10, 2023 ImmVira presented latest encouraging clinical results of two proprietary products at ASCO 2023 SHENZHEN, China, June 7, 2023 /PRNewswire/ -- ImmVira submitted four โฆSee details»
ImmVira and Shanghai Pharma Announce Clinical โฆ
Aug 6, 2020 Immvira Co., Ltd. was founded on May 18, 2015 by six scientists in the field of "tumor's oncolytic immunity" from the United States. The company develops innovative drugs for immunotherapy and ...See details»
Press Release
SHENZHEN, China, March 29, 2023 /PRNewswire/ -- ImmVira announced that its oncolytic virus product MVR-C5252 targeting malignant glioma obtained the approval from National Medical โฆSee details»
ImmVira's New-Generation Vector Poised to Enable CAR-T โฆ
Jan 25, 2022 ImmVira is a biotechnology company focused on genetically modified oncolytic viruses as potential cancer therapeutics. The company has developed science, technology โฆSee details»
ImmVira enters clinical development in combination therapy of โฆ
Apr 20, 2022 ImmVira is a biotechnology company focused on development of new generation novel anti-cancer drug vectors. Our advanced engineering created vectors that are highly โฆSee details»
MVR-T3011 - Drug Targets, Indications, Patents - Synapse - Patsnap
Dec 26, 2024 SHENZHEN, China, March 15, 2024 /PRNewswire/ -- ImmVira has recently announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track โฆSee details»
ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical
Sep 16, 2024 SHENZHEN, China, Sept. 15, 2024 /PRNewswire/ -- ImmVira announced the latest clinical results for its lead oncolytic virus product, MVR-T3011, via intravesical โฆSee details»
ImmVira enters clinical development in combination therapy of โฆ
Apr 19, 2022 MVR-T3011, ImmVira's proprietary 3-in-1oncolytic herpes simplex virus ("oHSV"), is a novel genetically engineered oHSV which aims to achieve the most favorable profile of โฆSee details»
ESMO 2024: ImmVira Presents Clinical Results of MVR-T3011 for โฆ
Sep 19, 2024 ImmVira recently revealed the latest clinical outcomes for its leading oncolytic virus product, MVR-T3011, administered intravesically to patients with high-risk BCG-failure โฆSee details»
ImmVira Reports Promising Phase I Results for Oncolytic Virus โฆ
Jun 27, 2024 ImmVira announced the latest clinical results for its lead oncolytic virus product, MVR-T3011, via intravesical administration in patients with high-risk BCG-failure non-muscle โฆSee details»
ImmVira's MVR-T3011 IV completed first 2 cohorts dose โฆ
Jan 18, 2022 ImmVira's CEO Dr. Guoying Zhou said, "The good news from MVR-T3011 IV clinical study is inspiring. Leveraging our proprietary OvPENS new drug R&D platform, we will โฆSee details»
ImmVira Says IV Administration of Oncolytic Herpes Simplex Virus โฆ
Jul 21, 2022 Shenzhen ImmVira announced its IV oncolytic herpes simplex virus (oHSV) therapy showed promising biodistribution after completing the first three dose escalations in a US trial โฆSee details»